JAZZ vs ZYME: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: JAZZ is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JAZZ and ZYME share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JAZZ and ZYME exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Jazz Pharmaceuticals is an Ireland-domiciled specialty biopharmaceutical company that develops and markets treatments in neuroscience and oncology. Its largest products are Xywav and Xyrem (low-sodium and legacy oxybates for narcolepsy and idiopathic hypersomnia) and Epidiolex/Epidyolex (a cannabidiol treatment for rare epilepsies), which together anchor a neuroscience portfolio generating several billion dollars a year. Jazz has expanded aggressively into oncology through Zepzelca (small cell lung cancer), Rylaze (pediatric leukemia), Ziihera/zanidatamab (a HER2-directed bispecific antibody) and Modeyso (dordaviprone for diffuse glioma, added via the 2025 Chimerix acquisition).

Full JAZZ guide

Zymeworks is a biotechnology company incorporated in Delaware with roughly 231 employees, built around protein engineering: bispecific antibodies and antibody-drug conjugates aimed mainly at cancer. Its one approved medicine, zanidatamab, is sold as Ziihera by Jazz Pharmaceuticals in the United States and other licensed markets and by BeOne Medicines across its Asia-Pacific territories. Zymeworks does not market anything itself. Revenue arrives as tiered royalties (10% to 20% of Jazz's net sales, up to 19.5% of BeOne's) and as regulatory and commercial milestone payments, while the wholly owned pipeline of ADCs stays in early clinical testing.

Full ZYME guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JAZZ drivers: Sleep franchise durability; Oncology pivot and Ziihera.
• ZYME drivers: Ziihera moves into first-line gastric cancer; A second cash-generating asset via Theravance.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Jazz is concentrated in a few large products, so any acceleration of generic or branded competition against Xywav or Epidiolex could pressure revenue and the stock. For ZYME, zymeworks is not profitable and is not close to it on current product economics: the second quarter of 2026 produced a net loss of about $45.0 million on roughly $4.6 million of revenue, and operations run on a ~$322.5 million cash and securities balance plus lumpy partner payments rather than on product profits.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JAZZ if you believe its drivers more; ZYME if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JAZZ and ZYME guides.

JAZZ. Jazz combines several billion dollars of high-margin drug revenue with strong non-GAAP earnings, yet trades at a comparatively low multiple relative to those profits. The gap reflects investor concern about patent cliffs and competition rather than current profitability. Net debt of roughly $3 billion means capital allocation and acquisition discipline matter to the equity story.

ZYME. The sales multiple is close to meaningless here because the revenue line mixes a small growing royalty with large one-off milestones, so it swings by an order of magnitude between years. A more useful frame is the two pieces separately: royalties of ~$1.8 million in the second quarter that track Jazz's Ziihera sales, and a milestone stack of up to ~$1.3 billion that pays only on events. Second-quarter research and development spending fell about 20% year over year to ~$27.4 million while general and administrative costs rose to ~$19.3 million, and management stopped issuing cash runway guidance in August 2026, citing the shift toward a revenue-generating model.

Headline figures (approximate, July 2026): JAZZ shows revenue (ttm) ~$4.3B, 2026 revenue guidance ~$4.25B to $4.5B, q1 2026 revenue ~$1.07B (up ~19% YoY), market cap ~$15B; ZYME shows revenue (ttm) ~$37.1M, royalty revenue (q2 2026) ~$1.8M, net loss (q2 2026) ~$45.0M, cash and marketable securities (jun 30, 2026) ~$322.5M.

JAZZ and ZYME are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JAZZ and ZYME exposure against your real portfolio. It is not an investment adviser.